1. Impact of the adolescent pertussis booster dose on the incidence of pertussis in British Columbia and Quebec, Canada.
- Author
-
Brousseau N, Skowronski DM, Bellemare D, Amini R, Joffres Y, Clarke Q, Quach C, Rallu F, Hoang L, and De Serres G
- Subjects
- Adolescent, British Columbia epidemiology, Child, Child, Preschool, Female, Humans, Immunization, Secondary methods, Incidence, Infant, Male, Quebec epidemiology, Whooping Cough diagnosis, Young Adult, Immunization, Secondary trends, Pertussis Vaccine therapeutic use, Whooping Cough epidemiology, Whooping Cough prevention & control
- Abstract
Impact of an adolescent tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine program was assessed in the provinces of British Columbia and Quebec, Canada. In both provinces, the Tdap booster has been in place since 2004, targeting Grade 9 students (14-15-years-of-age). Incidence rate ratios (IRRs) standardizing notification rates among teens 15-19-years-old to infants <1-year-old decreased following introduction of the Tdap program and were significantly halved during the 2009-2012 post-Tdap versus 2000-2003 pre-Tdap period. This program impact, however, is tempered by the observation that pertussis incidence among 15-19-year-olds was already lower than any other pediatric age group, following gradual decline from pre-teen rates even before the Tdap program. The risk of hospitalization among adolescents 15-19-years-old was also low throughout at <1/100,000. Furthermore, IRRs increased in 2013-2017 when an increasing proportion of 15-19-year-olds were primed with acellular pertussis vaccine only, suggesting short-lived Tdap booster-dose effectiveness that warrants further monitoring., (Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF